Pacific Edge Limited (ASX:PEB)
Australia flag Australia · Delayed Price · Currency is AUD
0.0980
-0.0020 (-2.00%)
Jul 3, 2025, 1:15 PM AEST

Pacific Edge Company Description

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients.

It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer.

It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a low risk of recurrence.

In addition, the company is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma.

Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Pacific Edge Limited
Country New Zealand
Founded 2001
Industry Diagnostics & Research
Sector Healthcare
Employees 114
CEO Peter Meintjes

Contact Details

Address:
Centre for Innovation
Dunedin, 9016
New Zealand
Phone 64 3 577 6733
Website pacificedgedx.com

Stock Details

Ticker Symbol PEB
Exchange Australian Securities Exchange
Fiscal Year April - March
Reporting Currency NZD
ISIN Number NZPEBE0002S1
SIC Code 2835

Key Executives

Name Position
Dr. Peter Meintjes Chief Executive Officer
Grant Gibson Chief Financial Officer
Darrell Morgan Chief Operating Officer
Dr. Justin Harvey Chief Technology Officer
Prof. Parry Guilford Ph.D. Chief Scientific Officer and Member of Scientific Advisory Board
Zoe O'Donnell Global Head of People and Culture
Andrew McIntosh Chief Digital Officer
Glen Costin President of Asia Pacific
Dr. Tamer Aboushwareb Chief Medical Officer
David Levison Executive Chairman and President of Pacific Edge Diagnostics USA